The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 329:1965 December 23, 1993 Number 26
NextNext

CD44 -- A New Prognostic Marker for Neuroblastoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: CD44 is a cell-surface glycoprotein involved in cell-cell and cell-matrix interactions1. CD44 isoforms are expressed during progression and metastasis in colon and breast cancer and in non-Hodgkin's lymphoma2,3,4. We investigated the prognostic importance of the expression of CD44 in neuroblastoma, one of the most common cancers in children.

CD44 expression was determined by immunostaining 52 neuroblastomas with a monoclonal antibody (J173) directed against an epitope common to all CD44 isoforms1. All tumors were from children with newly diagnosed neuroblastoma treated with standard protocols. The tumors were classified according to international criteria (stages 1 and . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.